

**XINGLEI CHAI, PH.D.**  
**Vice President**

Direct: 617 422 2619  
Fax: 617 425 8001  
xinglei.chai@analysisgroup.com

111 Huntington Avenue  
14th Floor  
Boston, MA 02199

Dr. Chai specializes in biostatistics and health economics and outcomes research (HEOR). She has extensive experience in developing and applying advanced statistical methods and machine learning tools to solve complex questions in the field of health outcomes research. Her expertise includes economic modeling, indirect treatment comparison, and real-world studies using clinical trial data, electronic medical records, medical chart reviews, and disease registries. Dr. Chai has also led submissions to health technology assessment agencies across the world, including those in the UK, France, Germany, Nordic countries, Canada, and Japan. Her work spans a variety of disease areas, such as oncology, blood disorders, autoimmune diseases, infectious diseases, women's health, and chronic kidney diseases. Dr. Chai's research has been published in many peer-reviewed journals and featured at various conferences.

**EDUCATION**

2017            Ph.D., biostatistics, University of Pennsylvania  
2014            M.S., biostatistics, University of Pennsylvania  
2011            B.A., mathematics and economics, University of Arizona

**PROFESSIONAL EXPERIENCE**

2017–Present    Analysis Group, Inc.  
                    *Vice President (2025–Present)*  
                    *Manager (2021–2024)*  
                    *Associate (2017–2020)*

**SELECTED PEER-REVIEWED JOURNAL PUBLICATIONS**

- Dickinson M, Martinez-Lopez J, Jousseau E, Yang H, **Chai X**, Xiang C, Wang T, Zhang J, Ramos R, Schuster SJ, Fowler N. “Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma.” *Leukemia & Lymphoma*. 2024 Mar;65(3):323–332.
- Guinan K, Mathurin K, Au Y, Schuh AC, Bui CN, **Chai X**, Lachaine J. “Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis.” *Current Oncology*. 2022 Oct 8;29(10):7524–36.
- Choi M, Song J, Bui CN, Ma E, **Chai X**, Yin L, Betts KA, Kapustyan T, Montez M, LeBlanc TW. “Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.” *Journal of Managed Care & Specialty Pharmacy*. 2022 Sep;28(9):980–8.

- Maziarz RT, Zhang J, Yang H, **Chai X**, Yuan C, Schwarz E, Jakovac M, Martinez-Prieto M, Agarwal A, Degtyarev E, Tam CS, Salles GA. “Indirect Comparison of Tisagenlecleucel and Historical Treatments for Relapsed/Refractory Diffuse Large B-cell Lymphoma.” *Blood Advances*. 2022 Apr;6(8):2536–2547.
- Pratz KW, **Chai X**, Xie J, Yin L, Nie X, Montez M, Iantuono E, Downs L, Ma E. “Cost Effectiveness Analysis of Venetoclax Plus Azacitidine Versus Azacitidine in Newly Diagnosed Adult Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy from a United States Payer Perspective.” *Blood*. 2021 Nov 23;138:112.
- Yu S, Smith A, Hass S, Wu E, **Chai X**, Zhou J, Ayyagari R, Liu JS, Robison D, Donelson SM, Tilles S. “The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy.” *Advances in Therapy*. 2021 Aug;38(8):4321–32.
- Wakase S, Teshima T, Zhang J, Ma Q, Fujita T, Yang H, **Chai X**, Qi CZ, Liu Q, Wu EQ, Igarashi A. “Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan.” *Transplantation and Cellular Therapy*. 2021 Jun;27(6):506.e1–506.e10.
- Wakase S, Teshima T, Zhang J, Ma Q, Watanabe Y, Yang H, Qi CZ, **Chai X**, Xie Y, Wu EQ, Igarashi A. “Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan.” *Transplantation and Cellular Therapy*. 2021 Mar;27(3):241.e1–241.e11.
- Yang H, Hao Y, **Chai X**, Qi CZ, Wu EQ. “Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital’s perspective.” *Journal of Medical Economics*. 2020 Sep 1;23(9):1016–24.
- Yang H, Hao Y, Qi CZ, **Chai X**, Wu EQ. “Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital’s Perspective.” *Journal of Managed Care & Specialty Pharmacy*. 2020 Aug;26(8):971–980.
- Zhang L, Shin VY, **Chai X**, Zhang A, Chan TL, Ma ES, Rebbeck TR, Chen J, Kwong A. “Breast and ovarian cancer penetrance of *BRCA1/2* mutations among Hong Kong women.” *Oncotarget*. 2018 Feb 2;9(38):25025–25033.
- **Chai X**, Domchek S, Kauff N, Rebbeck T, Chen J. “Re: Breast Cancer after Salpingo-Oophorectomy in Healthy *BRCA1/2* Mutation Carriers: Revisiting the Evidence for Risk Reduction.” *Journal of the National Cancer Institute*. 2015 Sep;107(9):d1v217.
- **Chai X**, Friebel TM, Singer CF, Gareth Evans D, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Tung N, Weitzel JN, Couch FJ, Hulick PJ, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Blum JL, Domcheck SM, Chen J, Rebbeck TR. “Use of Risk-Reducing Surgeries in a Prospective Cohort of 1,499 *BRCA1* and *BRCA2* Mutation Carriers.” *Breast Cancer Research and Treatment*. 2014 Nov;148(2):397–406.

## **SELECTED CONFERENCE PRESENTATIONS**

- Gong W, Diva U, Bensink M, **Chai X**, Xie Y, Gao S, Hendry B, Mercer A, Zhou Z, Rovin B, Barratt J. “Matching-Adjusted Indirect Comparisons of eGFR Slopes in the PROTECT Study With UK RaDaR IgA Nephropathy Population and the Control Arm of NefIgArd.” National Kidney Foundation Spring Clinical Meetings 2024, Long Beach, CA (May 14–18, 2024)
- Lotan Y, Yang M, **Chai X**, Ye D, Zhao A, Moradi A, Guo A. “Budget Impact Analysis of Nadofaragene Firadenovec (Adstiladrin) for the Treatment of High-Grade, Bacillus Calmette-Guerin Unresponsive Non-Muscle Invasive Bladder Cancer in the US.” Academy of Managed Care Pharmacy (AMCP) Annual Meeting, New Orleans, LA (April 15–18, 2024)
- Shah MA, Shitara K, Lonardi S, Chao Y, Yamaguchi K, Kukielka-Budny B, Ryu MH, Ungureanu A, Oh M, Chang L, Yang H, **Chai X**, Bhattacharya P, Matsangou M, Ranganath R, Ajani J, and Xu R. “Network meta-analysis of global trials of 1L therapies in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.” 2024 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium, San Francisco, CA (January 18–20, 2024)
- Bensink M, Gong W, **Chai X**, Gao S, Diva U, Hendry B, Mercer A, Zhou Z. “Matching-adjusted indirect comparison of sparsentan vs. delayed-release formulation budesonide for proteinuria reduction in adults with IgA nephropathy.” European Renal Association Congress, Milan and Virtual (June 15–18, 2023)
- Dickinson M, Martinez-Lopez J, Jousseau E, Anjos C, Yang H, **Chai X**, Xiang C, Wang T, Ramos R, Lobetti-Bodoni C, Schuster S, Fowler N. “Comparative Efficacy and Safety of Tisagenlecleucel and Axicabtagene Ciloleucel in Relapsed/Refractory Follicular Lymphoma.” EHA Annual Meeting, Vienna, Austria (June 9–12, 2022)
- Guinan K, Mathurin K, Au Y, Schuh A.C, Bui C.N, **Chai X**, and Lachaine J. “Venetoclax in Combination with Azacitidine is Cost-Effective vs. Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Perspective.” International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Virtual (May 15–18, 2022)
- Pratz K, Lachaine J, Suh HS, Li X, Schuh AC, **Chai X**, Xie J, Yin L, Bui CN. “Health State Utilities for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy.” ISPOR Europe, Virtual (2021)
- Schuh AC, Pratz K, Lachaine J, Suh HS, Li X, **Chai X**, Xie J, Gu C, Bui CN. “Projecting the Long-Term Benefits of Venetoclax Combination Therapies for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy: An Assessment of Net Health Benefit.” ISPOR Europe, Virtual (2021)
- LeBlanc T, Choi M, Ma E, Song J, **Chai X**, Betts K, Kapustyan T, Montez M, Bui C. “Budget impact analysis of venetoclax combination treatments in newly diagnosed acute myeloid leukemia in adults who are ineligible for intensive chemotherapy.” AMCP Annual Meeting, Virtual (April 12–16, 2021)

- Zhou Z, Li J, **Chai X**, Wang Y, Ejzykowicz F, Malcolm B, Kurt M, May J, Borrill J. “A study to assess the impact of incorporating the ‘probability of being in response function’ into an economic model for nivolumab in advanced renal cell carcinoma.” ISPOR Europe, Virtual (2020)
- Tilles S, Yu S, Smith A, Wu E, Zhou J, **Chai X**, Wei LJ, Robison D, Hass S, Donelson S, Vickery B. “THE ESTIMATED RISK REDUCTION OF ANAPHYLACTIC REACTIONS ASSOCIATED WITH AR101 ORAL IMMUNOTHERAPY FOLLOWING ACCIDENTAL PEANUT EXPOSURE: AN ANALYSIS BASED ON CLINICAL TRIAL DATA.” ISPOR, Orlando, FL (May 16–20, 2020)
- Yang H, Hao Y, Qi C, **Chai X**, Wu E. “Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a US Hospital’s Perspective.” American Society of Hematology (ASH) Annual Meeting, Orlando, FL (December 7–10, 2019)
- Yang H, Hao Y, Qi C, **Chai X**, Wu E. “Estimation of Total Costs in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Receiving Tisagenlecleucel from a US Hospital’s Perspective.” ASH Annual Meeting, Orlando, FL (December 7–10, 2019)
- Yang H, Ma Q, **Chai X**, Zhang J, Wu E, Kuzan D, Hao Y, Duteil E, Jewitt K, Schwarz E, Dondoni C, Saldana A, Jousseau E. “Estimation of the Healthcare Resource Utilization (HCRU) Costs in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Receiving Tisagenlecleucel: A Micro-costing Study in Europe.” ISPOR Europe, Copenhagen, Denmark (November 2–6, 2019)
- Choi M, Ravelo A, Keim H, Song J, **Chai X**, Betts K, Bui C, PharmD. “Budget impact analysis of venetoclax combinations in treatment of newly diagnosed acute myeloid leukemia in adults who are ineligible for intensive induction chemotherapy.” AMCP Annual Meeting, San Diego, CA (April 2019)
- Zhou Z, Parikh K, **Chai X**, Rokito A, Udeze C, Xie J, Agarwal A. “Cost-Effectiveness Analysis of Lenalidomide for Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Patients: A United States (US) Payer Perspective.” ASH Annual Meeting, San Diego, CA (December 1–4, 2018)
- Yang H, Han S, **Chai X**, Wu E, Abikoff C, Hao Y, Ferrusi I. “Budget impact associated with the introduction of tisagenlecleucel for the treatment of relapsed or refractory diffuse large b-cell lymphoma.” AMCP Nexus, Orlando, FL (October 22–25, 2018)
- **Chai X**, Chen J. “Design and Analyses of Two-Phase Studies for Predicting Binary Outcomes.” Joint Statistical Meetings, Chicago, IL (August 2016)
- **Chai X**, Chen J. “Design and Analyses of Two-Phase Studies for Predicting Binary Outcomes.” Eastern North American Region Spring Meeting, Austin, TX (March 2016)

## LANGUAGES

Chinese (native), English (proficient)